Novel molecular targeted and wide spectrum antitumor agents: Preparation and preclinical evaluation of IER5/Cdc25B targeted low-molecular-weight phospha sugar derivatives

Abstract

Novel broad spectrum low-molecular-weight antitumor agents of phospha sugar derivatives were investigated and developed. Branched deoxybromophospha sugars, such as DBMPP and TBMPP, which target IER5/Cdc25B and innovate in chemo-therapeutic treatments against various type of cancer cells. These successful preclinical in vitro and in vivo evaluations observed might be expected to afford clinically useful drugs and innovative medical treatments for various kinds of cancers.